Choice A reason: Cilostazol inhibits phosphodiesterase III, increasing cyclic AMP, which dilates arteries and reduces platelet aggregation. This improves blood flow and reduces intermittent claudication in PAD, directly targeting vascular symptoms by enhancing circulation and preventing thrombosis, making it a primary treatment option. Choice B reason: Ramipril, an ACE inhibitor, lowers blood pressure and protects vascular endothelium, benefiting PAD indirectly. It reduces cardiovascular strain but doesn’t directly improve limb perfusion or claudication, so it’s not a primary PAD medication despite its role in managing comorbidities like hypertension. Choice C reason: Metoprolol, a beta-blocker, slows heart rate and reduces myocardial oxygen demand, useful in heart disease. In PAD, it may worsen claudication by reducing peripheral blood flow via vasoconstriction, making it less commonly prescribed specifically for PAD management. Choice D reason: Aspirin inhibits cyclooxygenase, reducing thromboxane A2 and platelet aggregation. This antiplatelet action prevents clot formation in narrowed PAD arteries, improving outcomes by reducing thrombotic events, making it a standard, evidence-based therapy for symptom relief and risk reduction. Choice E reason: Clopidogrel blocks ADP receptors on platelets, preventing aggregation and thrombus formation. In PAD, it reduces ischemic events and improves patency, often used alone or with aspirin, making it a key medication for managing vascular complications and symptoms.